Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.8% Following Insider Selling

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was down 5.8% during trading on Thursday following insider selling activity. The company traded as low as $19.44 and last traded at $19.44. Approximately 54,219 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 476,887 shares. The stock had previously closed at $20.63.

Specifically, COO Pad Chivukula sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ARCT. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. HC Wainwright restated a "buy" rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a "strong-buy" rating in a report on Monday, August 12th. Finally, Leerink Partners assumed coverage on Arcturus Therapeutics in a report on Monday, August 12th. They set an "outperform" rating and a $70.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus price target of $71.40.

Arcturus Therapeutics Stock Performance

The stock has a market cap of $554.80 million, a price-to-earnings ratio of -5.28 and a beta of 2.61. The business's 50 day moving average is $21.06 and its 200 day moving average is $25.53.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to analysts' expectations of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter last year, the firm posted ($1.98) earnings per share. Research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently made changes to their positions in ARCT. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics in the 1st quarter valued at approximately $40,000. nVerses Capital LLC acquired a new position in shares of Arcturus Therapeutics in the third quarter worth $42,000. Quest Partners LLC raised its holdings in shares of Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock worth $90,000 after acquiring an additional 3,579 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Arcturus Therapeutics during the second quarter valued at $142,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 428 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.